Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 1월 2024 - 6:49AM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that on January 2,
2024, the Compensation Committee of Zentalis’ Board of Directors
granted non-qualified stock options to purchase an aggregate of
6,250 shares of the Company’s common stock to two newly hired
employees. The stock options were granted under the Zentalis
Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award
Plan (2022 Inducement Plan) as an inducement material to each such
individual’s entering into employment with Zentalis in accordance
with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Zentalis, or following a bona fide period of non-employment, as an
inducement material to each such individual’s entering into
employment with Zentalis, pursuant to Nasdaq Listing Rule
5635(c)(4).
The stock options have an exercise price of $15.99 per share,
which is equal to the closing price of Zentalis’ common stock on
The Nasdaq Global Market on the date of grant. The stock options
have a 10-year term and will vest over four years, with 25% of the
options vesting on the first anniversary of the vesting
commencement date and the remaining 75% of the options vesting in
equal monthly installments over the three years thereafter. Vesting
of the stock options is subject to the employee’s continued service
to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company’s lead product
candidate, azenosertib (ZN-c3), is a potentially first-in-class and
best-in-class WEE1 inhibitor for advanced solid tumors and
hematologic malignancies. Azenosertib is being evaluated as a
monotherapy and in combination across multiple clinical trials and
has broad franchise potential. In clinical trials, azenosertib has
been well tolerated and has demonstrated anti-tumor activity as a
single agent across multiple tumor types and in combination with
several chemotherapy backbones. As part of its azenosertib clinical
development program, the Company is exploring enrichment strategies
targeting tumors of high genomic instability, such as Cyclin E1
positive tumors and homologous recombination deficient tumors. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on X/Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Katie Beach Oltsik Evoke
CanaleKatherine.Beach@evokegroup.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024